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Available online 21 September 2015Patients exposed to benﬂuorex have an increased risk of restrictive organic valvular heart disease. Aortic and
mitral regurgitations caused by ﬁbrotic valve disease are the most common features observed in exposure to
fenﬂuramine derivatives in general and benﬂuorex in particular. We report here, for the ﬁrst time to our knowl-
edge, a well-documented case in which obstructive sub-aortic endocardium ﬁbrosis within the left ventricular
outﬂow tract is related with exposure to a drug that modiﬁes the metabolism of serotonin. It now remains to
be established whether extensive ﬁbrosis of the myocardium in addition to well-documented valvular ﬁbrosis
may develop in patients exposed to amphetamine-derived drugs affecting the serotonin system.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).A 67-year-old woman with dyspnea (NYHA functional class III) was
referred to our cardiology department for mitral and aortic valvular
heart diseases (VHDs). Her cardiac history included hypertension,
dyslipidemia, type 2 diabetes mellitus and overweight. She has been
exposed to benﬂuorex for eight years at 150 mg 3 times/day and has
also received metformin, glibenclamide, aspirin, verapamil and furose-
mide. Her resting systolic/diastolic blood pressure and heart rate were
120/60 mmHg and 70 beats/min, respectively. Clinical examination
revealed systolic aortic and mitral murmurs. Echocardiography re-
vealed moderate left ventricular (LV) hypertrophy, normal LV ejec-
tion fraction and sub-aortic signiﬁcant ﬂow obstruction (peak velocity
of 415 cm/s) due to septal sub-aortic hypertrophy without systolic
anterior motion of the mitral valve. A moderately thickened aortic
valve with a moderate central aortic regurgitation and a mitral valve
thickening with shortening of the chordae tendinae leading to moder-
ate mitral regurgitation without commissural fusion, both highly sug-
gestive of drug-induced VHD, were found. Doppler estimated systolic
pulmonary arterial pressure was 49 mmHg. The coronary angiography
was normal.aire d'Amiens, Département de
Amiens cedex 1, France.
(C. Tribouilloy).
land Ltd. This is an open access articlThe aortic valve and sub-aortic ﬁbrosis were removed and an
aortic bioprosthesis was inserted. Mitral valve repair was performed.
Intraoperative ﬁndings included an unusual sub-aortic circumferen-
tial ﬁbrosis stenosis (with no features suggesting congenital sub-
aortic stenosis) and retraction of the aortic cusps. The macroscopic
aspects of mitral and aortic valves but also of sub-aortic stenosis
were highly suggestive of drug-induced ﬁbrotic heart disease (Fig. 1).
Both sub-aortic valvular and endocardial ﬁbrosis were conﬁrmed by
pathological examination. Signiﬁcantﬁbrotic thickening of the endocar-
dium was found on the ventricular side of the aortic leaﬂets and
featured dense collagen ﬁbrosis and a low density of ﬁbroblasts typical
of drug-induced VHD (Fig. 2). The ﬁbrosa and spongiosa were normal
with no calciﬁcation and degenerative or rheumatic lesion. The ﬁbrotic
alterations of the sub-aortic sample (Fig. 2) in a histologic analysis were
typical of drug-induced toxicity. The post-operative course was
uneventful.
To the best of our knowledge, this is the ﬁrst report of sub-aortic en-
docardium ﬁbrosis within the left ventricular outﬂow tract related to
exposure to a drug involving serotonin metabolism. Benﬂuorex is an
amphetamine derivative related to fenﬂuramine and dexfenﬂuramine,
marketed for patients with hypertriglyceridemia and diabetes mellitus
but also used as an appetite suppresser [1]. It has been prescribed in
many countries in Europe, Africa, Asia, Latin America and the Caribbean.
Patients exposed to benﬂuorex as to fenﬂuramine present an increasede under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Macroscopic appearance of the surgical specimens, with the two fragments of sub-aortic ﬁbrosis (top) and the three aortic leaﬂets (bottom), centimeter scale. Left ventricular side
(Panel A) and aortic side (Panel B).
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activity of norfenﬂuramine [1], a common metabolite of fenﬂuramines
as well as of benﬂuorex. Aortic and mitral regurgitations caused by
ﬁbrotic valve disease are the most common VHDs observed in patients
exposed to fenﬂuramine derivatives. The stimulation by these drugs of
5-hydroxytryptamine 2B (5-HT2B) serotonin receptor (found in both
aortic and mitral valve tissues) upregulates transforming growth factor
ß, resulting in glycosaminoglycan production and proliferation of
ﬁbroblasts and smoothmuscle cells. The echocardiographic characteris-
tics of drug-induced VHDhave been thoroughly described [2]. There are
some data in rodents to suggest that 5-HT2B receptors are present not
only on heart valves but also in the non-valvular endocardium. Overex-
pression of the 5-HT2B receptor in the left ventricle of transgenic miceFig. 2.Majorﬁbrous thickening of the endocardium (arrows) on the ventricular aspect of the lea
(S) are normal without calciﬁcations. Hematoxylin-eosin stain: original X 2.5 (Panel A) and X 5
the endocardium, with abundant extracellular matrix and spindle cells X 2 (Panel C): this ﬁbro
tissue X 10 (Panel E). Hematoxylin-eosin stain.has been linked to left ventricular hypertrophy. Expression of 5-
HT2A and 5-HT2B receptors has been reported in ventricular heart
ﬁbroblasts [3]. In rats, it has been clearly demonstrated that 5-HT2B
agonists induce subendocardial cell proliferation especially in the
left heart [4]. The biological result of activating such receptors is mi-
tosis and secretion of inﬂammatory cytokines and extracellular ma-
trix components [3]. These effects lead to cardiac hypertrophic
remodeling, and, ultimately, impairment of ventricular function.
One can legitimately hypothesize that serotonin has a direct, mitogenic,
proliferative effect on cardiac non-valvular endocardial cells via 5-HT2B
receptor expression. This endocardo-myocardial ﬁbrosis might create
left ventricular remodeling and diastolic dysfunction leading to heart
failure in patients exposed to 5-HT2B agonist drugs. Thus, one case ofﬂet dense collagenﬁbrosiswith lowdensity ofﬁbroblasts. Theﬁbrosa (F) and the spongiosa
(Panel B). Histological appearance of the subvalvular ﬁbrotic tissue. Fibrous thickening of
us tissue is heterogeneous with dense collagen areas X 10 (Panel D) and loose connective
69C. Szymanski et al. / IJC Heart & Vasculature 9 (2015) 67–69restrictive cardiomyopathy was reported after fenﬂuramine–phenter-
mine exposure [5]. In the present case, sub-aortic endocardial involve-
ment responsible for severe non-valvular sub-aortic stenosis, considered
to be related to drug-induced toxicity, was found in a patient exposed
to benﬂuorex.
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